Cardiology Review - Issue 1/2017
7
11
Cardiotoxicity of anti-cancer drugs in experimental settings
M. Adamcová, M. Štěrba
14
Cardiotoxicity of anticancer treatment in patients with ovarian cancer
I. Sedláková, R. Pudil, R. Praus, V. Študent, J. Špaček
22
30
Cardiotoxicity – current guidelines
R. Pudil
34
Cardiotoxicity in haemato-oncological patients
B. Mladosievičová
39
Rivaroxaban – pharmacological profile
K. Urbánek
45
Edoxaban – pharmacological profile
R. Lábrová, K. Lábr
51
56
Modern antithrombotic treatment after ACS – do we use it adequately?
J. Špinar, J. Vítovec
62
COSYREL – a drug for patients with coronary artery disease and heart failure
J. Špinar, J. Vítovec
68
Beta-blockers in chronic heart failure as recorded in the FAR NHL registr
K. Lábr, J. Špinar, J. Pařenica, L. Špinarová, F. Málek, M. Špinarová, O. Ludka, J. Jarkovský, K. Benešová, R. Lábrová
Cardiology Review
2017 Číslo 1
Najčítanejšie v tomto čísle
- Diuretics and mineralocorticoid receptor antagonists in the therapy of chronic heart failure with reduced left ventricular ejection fraction
- COSYREL – a drug for patients with coronary artery disease and heart failure
- Rivaroxaban – pharmacological profile
- Late consequences of cardiotoxicity